Does Kaiser Cover Stem Cell Therapy? Transplants vs. Injections

Kaiser Permanente covers stem cell therapy when it takes the form of a blood or marrow transplant for certain cancers, blood disorders, immune deficiencies, and a short list of other serious conditions. It does not cover stem cell injections for joint pain, arthritis, tendon injuries, or other regenerative and orthopedic uses, which Kaiser classifies as investigational. The split tracks what the FDA has approved: hematopoietic stem cell transplantation is established medicine, while mesenchymal stem cell products for musculoskeletal repair are not.

Conditions Kaiser Will Cover a Transplant For

Kaiser’s clinical review criteria authorize autologous transplants (your own cells) and allogeneic transplants (donor cells) for end-stage or life-threatening diseases where other therapies are unlikely to cure or extend life. The transplant physician decides which type based on the disease, remission status, and donor availability, following guidelines from the National Comprehensive Cancer Network and the American Society of Blood and Marrow Transplantation.1Kaiser Permanente Washington. Stem Cell Transplantation Clinical Review Criteria

Covered diagnoses include:

  • Acute myelogenous leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia after failure of tyrosine kinase inhibitors, high-risk or resistant chronic lymphocytic leukemia, juvenile myelomonocytic leukemia, and biphenotypic leukemia
  • Hodgkin lymphoma after induction failure or relapse, and non-Hodgkin lymphoma including follicular, diffuse large B-cell, mantle cell, and T-cell subtypes
  • Symptomatic multiple myeloma or myeloma with end-organ damage, high-risk myelodysplastic syndromes, and myeloproliferative neoplasms
  • Severe aplastic anemia, Fanconi anemia, and paroxysmal nocturnal hemoglobinuria
  • Thalassemia major and sickle cell disease with recurrent crises, acute chest syndrome, or high stroke risk
  • Severe combined immunodeficiency, Wiskott-Aldrich syndrome, Hurler syndrome, and adrenoleukodystrophy
  • Autologous transplants only for high-risk neuroblastoma, relapsed germ cell neoplasms, relapsed Wilms tumors, certain malignant brain tumors in young children, and relapsed Ewing sarcoma
  • Autologous transplant for systemic sclerosis in adults aged 18 to 70 who meet SCOT trial criteria

These indications track closely with national consensus guidelines.1Kaiser Permanente Washington. Stem Cell Transplantation Clinical Review Criteria

Multiple sclerosis is not on the list. Kaiser’s technology review committee rejected high-dose chemotherapy with stem cell rescue for MS in 1999, and the determination has not been updated.1Kaiser Permanente Washington. Stem Cell Transplantation Clinical Review Criteria

What Kaiser Will Not Pay For

Stem Cell Injections for Joints, Arthritis, and Tendons

Kaiser considers mesenchymal stem cell therapy investigational for every orthopedic application, including the repair or regeneration of musculoskeletal tissue or joints.1Kaiser Permanente Washington. Stem Cell Transplantation Clinical Review Criteria A Kaiser patient education document on arthritis describes stem cell injections for osteoarthritis as “high risk, low reward,” pointing out that the therapy is not FDA-approved for that use, has very few quality studies, has not been shown to be effective, carries unknown risks, and involves significant costs and conflicts of interest.2Kaiser Permanente. Kaiser Vacaville Arthritis Class

Practically, that means Kaiser providers will not perform these procedures, and members who seek them out at independent clinics will pay the full price with no reimbursement. Typical out-of-pocket costs run $5,000 to $8,000 per joint, and more invasive protocols using bone marrow or fat tissue extraction can reach $15,000 to $30,000.

Platelet-Rich Plasma

Kaiser classifies platelet-rich plasma injections as not medically necessary for musculoskeletal conditions, including knee osteoarthritis, plantar fasciitis, and tendinopathy. The insurer’s reviews have found insufficient evidence that PRP is as safe as standard therapies or produces better long-term outcomes.3Kaiser Permanente Washington. Platelet Rich Plasma Clinical Review Criteria

The Broader Regulatory Picture

Kaiser is not an outlier here. The only stem cell-based treatment currently approved by the FDA is hematopoietic stem cell transplantation for cancers and disorders of the blood and immune system.4Harvard Stem Cell Institute. Stem Cell Therapies Cigna’s 2025 medical policy deems stem cell therapy not medically necessary for all orthopedic and musculoskeletal conditions,5Cigna. Stem Cell Therapy Coverage Position Criteria UnitedHealthcare’s Community Plan classifies autologous cellular therapy as “unproven and not medically necessary for all indications,”6UnitedHealthcare. Autologous Cellular Therapy Medical Policy and Aetna considers mesenchymal stem cell transplantation experimental for autoimmune diseases.7Aetna. Hematopoietic Cell Transplantation for Non-Malignant Conditions

Qualifying for a Covered Transplant

A covered diagnosis is the first hurdle, not the last. Kaiser’s health encyclopedia says doctors generally look for candidates younger than 70 with no major comorbidities such as heart disease or diabetes, and with normal kidney and liver function.8Kaiser Permanente. Autologous Stem Cell Transplant Patients whose cancer is aggressive and widely spread are typically not considered good candidates, while patients with relapsed disease often are.9Kaiser Permanente. Allogeneic Stem Cell Transplant

For myeloablative conditioning regimens, Kaiser’s criteria add specific thresholds. An ejection fraction below 45 percent, lung function below 50 percent of predicted, creatinine clearance below 60 ml/min (with exceptions for myeloma and amyloidosis), or elevated bilirubin and transaminases can disqualify a patient.10OpenPayer. Kaiser Permanente Stem Cell Transplant Policy Update Reduced-intensity regimens, used more often in allogeneic settings, carry somewhat less stringent organ function requirements.1Kaiser Permanente Washington. Stem Cell Transplantation Clinical Review Criteria

Referrals are also contraindicated for patients with uncontrollable active infections, significant irreversible neurological dysfunction, active psychiatric conditions, or inadequate caregiver support. Candidates with a substance abuse history must show six months of documented abstinence.10OpenPayer. Kaiser Permanente Stem Cell Transplant Policy Update Patients and caregivers also need to be willing and able to travel to a Kaiser-approved Center of Excellence on short notice and return for complications.1Kaiser Permanente Washington. Stem Cell Transplantation Clinical Review Criteria Stem cell storage is covered only for members currently scheduled for a transplant.

If You Have a Kaiser Medicare Advantage Plan

Medicare Advantage members are also bound by CMS National Coverage Determinations. The current NCD 110.23, effective March 6, 2024, covers allogeneic hematopoietic stem cell transplantation for leukemia, aplastic anemia, severe combined immunodeficiency, and Wiskott-Aldrich syndrome, plus myelodysplastic syndromes in patients meeting specific prognostic thresholds. Coverage for multiple myeloma, myelofibrosis, and sickle cell disease under Medicare requires participation in a Medicare-approved prospective clinical study.11CMS. NCD 110.23 Stem Cell Transplantation

Autologous transplants are covered for acute leukemia in remission, resistant non-Hodgkin lymphoma, recurrent neuroblastoma, advanced Hodgkin disease, multiple myeloma meeting specific criteria, and primary AL amyloidosis. They are explicitly not covered for acute leukemia not in remission, chronic granulocytic leukemia, or most solid tumors other than neuroblastoma.11CMS. NCD 110.23 Stem Cell Transplantation

Confirming Coverage for Your Plan

Kaiser repeats throughout its clinical criteria that coverage varies by individual health plan. The clinical guidelines guide benefit administration but do not guarantee coverage for any particular member. To confirm whether a specific service is covered, review your Evidence of Coverage or Summary Plan Description, or call Member Services at 1-888-901-4636.1Kaiser Permanente Washington. Stem Cell Transplantation Clinical Review Criteria Federal employee plan members should check their member contract directly, since covered diagnoses and transplant types may differ.

Appealing a Denial

When Kaiser denies a stem cell transplant request, the denial notice includes the specific rationale and instructions for appeal.12Kaiser Permanente Washington. Clinical Review Criteria Non-Medicare appeals are resolved within 14 to 30 days. Medicare Advantage timelines depend on the part: Part C pre-service requests take up to 30 days, Part D pre-service up to 7 days, and post-service requests run from 14 to 60 days.

If the standard timeline could jeopardize life, health, or the ability to regain function, request an expedited appeal with a 72-hour resolution. A provider can initiate the expedited appeal without the member’s permission when clinical criteria are met and should submit supporting records within 24 hours.

Medicare Advantage denials that are upheld on internal appeal are automatically sent for external review. Commercial plan members may request external review within 180 days of the upheld denial. California residents in Kaiser HMO plans also have access to the Independent Medical Review process through the Department of Managed Health Care, which maintains a searchable database of past IMR decisions dating back to 2001.13California Department of Managed Health Care. Independent Medical Review and Complaint Reports